home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630466.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
32 lines
Document 0466
DOCN M9630466
TI Prospective clinical trial of high-purity factor VIII preparations in
haemophiliacs.
DT 9603
AU Varon D; National Hemophilia Center, Chaim Sheba Medical Center,;
Tel-Hashomer, Israel.
SO Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S82-3. Unique Identifier :
AIDSLINE MED/96076205
AB An assessment of the immune status of both HIV-positive and HIV-negative
haemophiliacs showed hypo-responsive and anergic patients in both
groups. In HIV-positive patients, the immune suppression, in addition to
HIV itself, may be caused by other viral infections such as all types of
hepatitis as well as by factor VIII concentrates. The introduction of
new technologies for preparing factor VIII concentrates led to the
question of whether higher purity is associated with a protective effect
on the immune system, which might improve the clinical course of
HIV-positive patients. Factor VIII from two manufacturing processes was
investigated, one prepared using an ion-exchange S/D step, and the other
utilizing a monoclonal antibody step. It is concluded that changing the
product, from the monoclonal antibody to the ion-exchange and vice versa
in the HIV-negative patients does not cause a change in the immune
profiles.
DE Chromatography, Ion Exchange Factor VIII/*ISOLATION & PURIF/THERAPEUTIC
USE Follow-Up Studies Hemophilia/*IMMUNOLOGY Human *HIV
Seronegativity *HIV Seropositivity Prospective Studies CLINICAL TRIAL
CONTROLLED CLINICAL TRIAL JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).